医院获得性与呼吸机相关细菌性肺炎试验趋势分析
该分析纳入2015年后提交FDA的4项三期非劣效试验(2433例),主要入组革兰阴性菌感染患者。28天全因死亡率为17.1%,其中通气HABP为31.9%、VABP为19.0%、非通气HABP为9.9%。年龄、南美居住地、通气HABP或VABP诊断及鲍曼不动杆菌感染与28天全因死亡相关。
要点
- 28天全因死亡率通气HABP 31.9%、VABP 19.0%、非通气HABP 9.9%。
- 鲍曼不动杆菌感染与28天全因死亡独立相关,东欧分离株美罗培南耐药率最高。
- 试验平均招募速度仅0.17例/中心/月,提示入组效率挑战。
核心结论
- 近期HABP/VABP试验分析可辅助未来开发项目的试验设计,并促进严重感染患者所需抗菌药物研发。
研究设计与样本
- 分析2015年后提交美国FDA的4项三期非劣效试验,共2433例参与者,所有试验主要入组革兰阴性菌感染患者。
主要发现
- 试验平均时长2.7年,平均招募速度0.17例/中心/月。
- 28天全因死亡率为17.1%,通气HABP为31.9%、VABP为19.0%、非通气HABP为9.9%。
- 多因素logistic回归显示年龄、南美居住地、通气HABP或VABP诊断及鲍曼不动杆菌感染与28天全因死亡相关。
- 鲍曼不动杆菌感染在东欧和亚太参与者中最常见,东欧分离株美罗培南耐药水平最高。
- 合并非研究抗菌药物最常见为β-内酰胺类,西欧起始最早。
临床怎么用
- 设计HABP/VABP试验时应考虑入组速度慢、死亡率因通气状态而异及鲍曼不动杆菌感染的地域耐药差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: New drug development for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) is critical. Challenges remain in the conduct of HABP/VABP trials, especially in the contexts of enrollment, endpoints, nonstudy antibacterial drug therapy, and antimicrobial resistance. METHODS: Four Phase 3 noninferiority trials (n = 2433 participants) submitted to the Food and Drug Administration after 2015 were analyzed for enrollment statistics, participant characteristics associated with 28-day all-cause mortality (ACM), microbiology, and receipt of nonstudy antibacterial drugs. All trials primarily enrolled patients with gram-negative bacterial infections. RESULTS: The mean trial length was 2.7 years and the mean recruitment rate was 0.17 participants/site/month. ACM at 28 days was 17.1% and was higher among participants diagnosed with ventilated HABP (31.9%) or VABP (19.0%) than nonventilated HABP (9.9%). VABP participants tended to be younger, less likely to have chronic obstructive pulmonary disease, and more likely to have previously sustained an injury. Age, South American residence, diagnosis of ventilated HABP or VABP, and Acinetobacter baumannii infection were all associated with 28-day ACM in a multivariate logistic regression model. Infection by A. baumannii was most common in Eastern European and Asia/Pacific participants, and Eastern European isolates exhibited the highest levels of meropenem resistance. Concomitant nonstudy antibacterial drug therapy most commonly included beta-lactams and was initiated earliest in Western Europe. CONCLUSION: This analysis of recent trials may assist in trial considerations for HABP/VABP development programs and promote needed antibacterial drug development for patients with serious infections.
引用
- Bart SM, Rubin D, Kim P, et al. Trends in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Trials. Clin Infect Dis. 2021. PMID: 33173946. doi:10.1093/cid/ciaa1712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。